| Prev Close | 2.27 |
| Open | 2.26 |
| Day Low/High | 2.13 / 2.27 |
| 52 Wk Low/High | 0.93 / 2.88 |
| Volume | 300.85K |
| Avg Volume | 358.80K |
Latest News
PSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date And Conference Call Information
Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th
PSivida Submits New Drug Application (NDA) For Durasert™ Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA
Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases
HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
Sustained Release Technology Well Tolerated and Provides Pain Reduction
PSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date And Conference Call Information
Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th
PSivida And Nicox Enter Strategic Collaboration Agreement To Develop Sustained Release Drug To Lower Intraocular Pressure In Patients With Glaucoma
Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds
First Week of January 2018 Options Trading For pSivida (PSDV)
Investors in pSivida Corp saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.